Thyrocare Technologies
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Thyrocare Technologies is positioned for robust growth, driven by a strategic focus on specialty diagnostics and an aggressive expansion of its franchise network. Management's guidance of 15-20% revenue growth for FY27 reflects confidence in the company's ability to penetrate deeper into the market and capitalize on high-margin offerings. The recent strong performance in pathology, coupled with the introduction of advanced diagnostic tests, supports Vista's forecast of stable margins and moderate revenue growth. However, increased competition from online diagnostics firms and potential pricing pressures present challenges that could impact profitability. The healthcare sector's overall positive trajectory, supported by rising demand for organized tertiary care, further underpins Thyrocare's outlook. Over the next 12-24 months, key opportunities include the expansion of the franchise network and the introduction of new diagnostic services, while watchpoints include the performance of the imaging business and the impact of competitive pressures on pricing. Overall, Vista's expected upside aligns with the company's growth strategy and market conditions, reinforcing a fair valuation and a positive investment outlook
Why We Like This Stock
- Management's guidance of 15-20% revenue growth for FY27 reflects strong confidence in market penetration and specialty diagnostics
- The aggressive expansion of the franchise network is expected to enhance market reach and drive volume growth
- The healthcare sector's positive trajectory, particularly in organized tertiary care, supports sustained demand for Thyrocare's services
Things To Watch Out For
- Increased competition from online diagnostics firms poses a risk to market share and pricing power
- The underperformance of the imaging business may necessitate strategic adjustments, including potential demergers
- Pricing pressures from competitive dynamics could impact profitability and margin stability
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 572 | 687 | 829 | 899 | 1,039 |
| Profit Before Tax (Cr.) | 97 | 137 | 219 | 262 | 297 |
| PBT Margin | 16.9% | 20.0% | 2643.7% | 29.2% | 28.6% |
| Net Profit (Cr.) | 66 | 93 | 160 | 190 | 216 |
| Earnings Per Share | 4.2 | 5.9 | 10.0 | 11.9 | 13.5 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| BKSecurities | ▲ Buy | 615 | 22-Jun-2026 |
| Elara Capital | ▲ Buy | 669 | 24-Jul-2026 |
| ICICI Securities | ▲ Buy | 650 | 24-Jul-2026 |
Company Overview
Show Company Profile
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.